相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
H. Paripati et al.
LEUKEMIA (2008)
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients
A. Mazumder et al.
LEUKEMIA (2008)
被撤回的出版物: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma:: results of a multicenter randomized clinical trial (Retracted article. See vol. 113, pg. 6265, 2009)
Abderrahman Abdelkefi et al.
BLOOD (2008)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M. Lokhorst et al.
HAEMATOLOGICA (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Phase II Pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma:: Efficacy and clinical implications of tumor response kinetics
Laura Rosinol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Pieter Sonneveld et al.
HAEMATOLOGICA (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A. Chanan-Khan et al.
BLOOD (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
A. K. Stewart et al.
LEUKEMIA (2007)
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
V. Sagaster et al.
LEUKEMIA (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N. C. Gutierrez et al.
LEUKEMIA (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
Maria-Victoria Mateos et al.
BLOOD (2006)
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Linda B. Baughn et al.
CANCER RESEARCH (2006)
Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in human immune system Rag2-/- γc-/- mice
N Legrand et al.
BLOOD (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Suzanne Trudel et al.
BLOOD (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Premilinary results of an IFM phase II study
JL Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
S Jagannath et al.
CANCER (2005)
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
S Kumar et al.
BONE MARROW TRANSPLANTATION (2004)
DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
CK Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
